Adoptive T-cell transfer in melanoma

Immunotherapy

Volumn 5, Issue 1, 2013, Pages 79-90

  Itzhaki, Orit ^a   Levy, Daphna ^a   Zikich, Dragoslav ^a   Treves, Avraham J ^a   Markel, Gal ^a,b   Schachter, Jacob ^a   Besser, Michal J ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

ACT; adoptive cell transfer; CAR; chimeric antigen receptor; genetically modified T cell; melanoma; TIL; tumor infiltrating lymphocyte

Indexed keywords

CANCER TESTIS ANTIGEN; CHEMOKINE; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; FLUDARABINE; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; NY ESO 1 ANTIGEN; SSX2 ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VEMURAFENIB;

ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE CONTROL; DNA MODIFICATION; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY CANCER; LYMPHOCYTE HOMING; LYMPHOCYTE TRANSFER; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; METASTATIC MELANOMA; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RECEPTOR GENE; T LYMPHOCYTE SUBPOPULATION; TRANSGENE; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; WHOLE BODY RADIATION;

CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; RECEPTORS, ANTIGEN, T-CELL; TREATMENT OUTCOME;

EID: 84871572488     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.143     Document Type: Review

References (110)

1. Gloster HM Jr, Brodland DG. The epidemiology of skin cancer. Dermatol. Surg. 22(3), 217-226 (1996).
2. Houghton AN, Polsky D. Focus on melanoma. Cancer Cell 2(4), 275-278 (2002).
3. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011).
4. Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
5. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer Y what clinicians need to know. Nat. Rev. Clin. Oncol. 8(10), 577-585 (2011).
6. Kirkwood JM, Tarhini AA, Panelli MC et al. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 26(20), 3445-3455 (2008).
7. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: Current status and future prospects. Oncologist 16(1), 5-24 (2011).
8. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105-2116 (1999).
9. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann. Surg. 228(3), 307-319 (1998).
10. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. J. Exp. Clin. Cancer Res. 19(1), 21-34 (2000).
11. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183(3), 725-729 (1996).
12. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004).
13. Yannelli JR, Wroblewski JM. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 23(1), 97-113 (2004).
14. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Failure of cancer vaccines: The significant limitations of this approach to immunotherapy. Anticancer Res. 20(4), 2665-2676 (2000).
15. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: Are we there yet? Immunol. Rev. 239(1), 27-44 (2011).
16. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
17. Davis ID, Brady B, Kefford RF et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: A Phase IIa trial. Clin. Cancer Res. 15(6), 2123-2129 (2009).
18. Le HK, Graham L, Miller CH, Kmieciak M, Manjili MH, Bear HD. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol. Immunother. 58(10), 1565-1576 (2009).
19. Tarhini AA, Millward M, Mainwaring P et al. A Phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115(4), 859-868 (2009).
20. Hoos A, Ibrahim R, Korman A et al. Development of ipilimumab: Contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 37(5), 533-546 (2010).
21. Thumar Jr, Kluger HM. Ipilimumab: A promising immunotherapy for melanoma. Oncology (Williston Park) 24(14), 1280-1288 (2010).
22. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
23. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
24. Inozume T, Hanada K, Wang QJ et al. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J. Immunother. 33(9), 956-964 (2010).
25. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
26. Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233-5239 (2008).
27. Radvanyi LG, Bernatchez C, Zhang M et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-12-1177 (2012) (Epub ahead of print).
28. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550-4557 (2011).
29. Smith FO, Downey SG, Klapper JA et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 14(17), 5610Y 5618 (2008).
30. Rosenberg SA. Raising the bar: The curative potential of human cancer immunotherapy. Sci. Transl. Med. 4(127), 127ps128 (2012).
31. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 29(11), 550-557 (2011).
32. Erdag G, Schaefer JT, Smolkin ME et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 72(5), 1070-1080 (2012).
33. Ladanyi A, Kiss J, Somlai B et al. Density of DC-LAMP+ mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol. Immunother. 56(9), 1459-1469 (2007).
34. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319(25), 1676-1680 (1988).
35. Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86(15), 1159-1166 (1994).
36. Antony PA, Piccirillo CA, Akpinarli A et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174(5), 2591-2601 (2005).
37. Gattinoni L, Finkelstein SE, Klebanoff CA et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202(7), 907-912 (2005).
38. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26(2), 111-117 (2005).
39. Wrzesinski C, Paulos CM, Kaiser A et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 33(1), 1-7 (2010).
40. Itzhaki O, Hovav E, Ziporen Y et al. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J. Immunother. 34(2), 212-220 (2011).
41. Besser MJ, Shapira-Frommer R, Treves AJ et al. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J. Immunother. 32(4), 415-423 (2009).
42. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J. Sci. Am. 6(Suppl. 1), S11-S14 (2000).
43. Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J. Immunol. 173(12), 7622-7629 (2004).
44. Dudley ME, Gross CA, Langhan MM et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 16(24), 6122-6131 (2010).
45. Hong JJ, Rosenberg SA, Dudley ME et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16(19), 4892-4898 (2010).
46. Besser MJ, Shapira-Frommer R, Treves AJ et al. Clinical responses in a Phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16(9), 2646-2655 (2010).
47. Murphy A, Westwood JA, Teng MW, Moeller M, Darcy PK, Kershaw MH. Gene modification strategies to induce tumor immunity. Immunity 22(4), 403-414 (2005).
48. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3(1), 35-45 (2003).
49. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006).
50. Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3), 535-546 (2009).
51. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5(8), 615-625 (2005).
52. Robbins PF, Morgan RA, Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29(7), 917-924 (2011).
53. Bendle GM, Linnemann C, Hooijkaas AI et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16(5), 565-570 (2010).
54. Cartellieri M, Bachmann M, Feldmann A et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J. Biomed. Biotechnol. 2010, 956304 (2010).
55. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR z chain. J. Immunol. 172(1), 104-113 (2004).
56. Burns WR, Zhao Y, Frankel TL et al. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 70(8), 3027-3033 (2010).
57. Erfurt C, Muller E, Emmerling S et al. Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients. Int. J. Cancer 124(10), 2341-2346 (2009).
58. Lo AS, Ma Q, Liu DL, Junghans RP. Anti-GD3 chimeric sFv-CD28/T cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin. Cancer Res. 16(10), 2769-2780 (2010).
59. Yvon E, del Vecchio M, Savoldo B et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin. Cancer Res. 15(18), 5852-5860 (2009).
60. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3(95), 95ra73 (2011).
61. Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011).
62. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011).
63. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12), 2709-2720 (2012).
64. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12(4), 269-281 (2012).
65. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a Phase I clinical trial. Mol. Ther. 18(4), 666-668 (2010).
66. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: Genetic modification to redirect effector cell specificity. Cancer J. 16(4), 336-341 (2010).
67. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21(2), 215-223 (2009).
68. Hunder NN, Wallen H, Cao J et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358(25), 2698-2703 (2008).
69. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17(19), 6287-6297 (2011).
70. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107(6), 2409-2414 (2006).
71. Cesana GC, Deraffele G, Cohen S et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24(7), 1169-1177 (2006).
72. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ Regulatory T cells in melanoma: The final hurdle towards effective immunotherapy? Lancet Oncol. 13(1), e32-e42 (2012).
73. Gattinoni L, Klebanoff CA, Palmer DC et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115(6), 1616-1626 (2005).
74. Pouw N, Treffers-Westerlaken E, Kraan J et al. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol. Immunother. 59(6), 921-931 (2010).
75. Hervas-Stubbs S, Mancheno U, Riezu-Boj JI et al. CD8 T cell priming in the presence of IFN-A renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: Important traits for adoptive T cell therapy. J. Immunol. 189(7), 3299-3310 (2012).
76. Rosenberg SA, Sportes C, Ahmadzadeh M et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 29(3), 313-319 (2006).
77. Jaleco S, Swainson L, Dardalhon V, Burjanadze M, Kinet S, Taylor N. Homeostasis of naive and memory CD4+ T cells: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis. J. Immunol. 171(1), 61-68 (2003).
78. Hinrichs CS, Spolski R, Paulos CM et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111(11), 5326-5333 (2008).
79. Pouw N, Treffers-Westerlaken E, Mondino A, Lamers C, Debets R. TCR gene-engineered T cell: Limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity. Mol. Immunol. 47(7-8), 1411-1420 (2010).
80. Mondino A, Dardalhon V, Hess Michelini R, Loisel-Meyer S, Taylor N. Redirecting the immune response: Role of adoptive T cell therapy. Hum. Gene Ther. 21(5), 533-541 (2010).
81. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153(4), 1687-1696 (1994).
82. Su X, Zhang L, Jin L et al. Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma. Cancer Biother. Radiopharm. 25(4), 465-470 (2010).
83. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A Phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non- Hodgkin lymphoma. Biol. Blood Marrow Transplant. 11(3), 181-187 (2005).
84. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: A pilot clinical trial. Hematol. Oncol. 27(3), 130-139 (2009).
85. Su X, Zhang L, Wu S et al. Cascading adoptive cell therapy for metastatic melanoma. Cancer Biother. Radiopharm. 26(3), 401-406 (2011).
86. Wu R, Forget MA, Chacon J et al. Adoptive T cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: Current status and future outlook. Cancer J. 18(2), 160-175 (2012).
87. Klebanoff CA, Gattinoni L, Palmer DC et al. Determinants of successful CD8+ T cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17(16), 5343-5352 (2011).
88. Wang A, Chandran S, Shah SA et al. The stoichiometric production of IL-2 and IFN-g mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci. Transl. Med. 4(149), 149ra120 (2012).
89. Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105(1), 241-250 (2005).
90. Prieto PA, Durflinger KH, Wunderlich JR, Rosenberg SA, Dudley ME. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J. Immunother. 33(5), 547-556 (2010).
91. Martin-Orozco N, Muranski P, Chung Y et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(5), 787-798 (2009).
92. Muranski P, Borman ZA, Kerkar SP et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35(6), 972-985 (2011).
93. Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4+ T cells. Curr. Opin. Immunol. 21(2), 200-208 (2009).
94. Turin I, Pedrazzoli P, Tullio C et al. GMP production of anti-tumor cytotoxic T cell lines for adoptive T cell therapy in patients with solid neoplasia. Cytotherapy 9(5), 499-507 (2007).
95. Montagna D, Turin I, Schiavo R et al. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy 14(1), 80-90 (2012).
96. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv. Immunol. 90, 51-81 (2006).
97. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273 (2000).
98. Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot MA, Ruiz-Cabello F, Garrido F. MHC class I antigens and immune surveillance in transformed cells. Int. Rev. Cytol. 256, 139-189 (2007).
99. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18(2), 89-95 (1997).
100. del Campo AB, Carretero J, Aptsiauri N, Garrido F. Targeting HLA class I expression to increase tumor immunogenicity. Tissue Antigens 79(3), 147-154 (2012).
101. del Campo AB, Aptsiauri N, Mendez R et al. Efficient recovery of HLA class I expression in human tumor cells after b2-microglobulin gene transfer using adenoviral vector: Implications for cancer immunotherapy. Scand. J. Immunol. 70(2), 125-135 (2009).
102. Abastado JP. The next challenge in cancer immunotherapy: Controlling T cell traffic to the tumor. Cancer Res. 72(9), 2159-2161 (2012).
103. Peng W, Ye Y, Rabinovich BA et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res. 16(22), 5458-5468 (2010).
104. Sapoznik S, Ortenberg R, Galore-Haskel G et al. CXCR1 as a novel target for directing reactive T cells toward melanoma: Implications for adoptive cell transfer immunotherapy. Cancer Immunol. Immunother. 61(10), 1833-1847 (2012).
105. Nizar S, Meyer B, Galustian C, Kumar D, Dalgleish A. T regulatory cells, the evolution of targeted immunotherapy. Biochim. Biophys. Acta 1806(1), 7-17 (2010).
106. Sutmuller RP, Den Brok MH, Kramer M et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 116(2), 485-494 (2006).
107. Boni A, Cogdill AP, Dang P et al. Selective BRAFV600E inhibition enhances T cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70(13), 5213-5219 (2010).
108. Wilmott JS, Long GV, Howle JR et al. Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18(5), 1386-1394 (2011).
109. Comin-Anduix B, Chodon T, Sazegar H et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin. Cancer Res. 16(24), 6040-6048 (2010).
110. Koya RC, Mok S, Otte N et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 72(16), 3928-3937 (2012).